Johnson & Johnson disclosed in a regulatory filing Tuesday that its Janssen Pharmaceuticals Inc. subsidiary received a civil investigative demand from the U.S. Attorney’s Office related to contractual relationships with pharmacy benefit managers. The demand was issued in connection with an investigation under the False Claims Act, and covers the period from Jan. 1, 2006 to the present. J&J’s stock, which was still inactive in premarket trade, has surged 11% year to date, while the Dow Jones Industrial Average has gained 1.6%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News